Symbiotec Pharmalab IPO Subscribes 3x+ on Day 2

The Symbiotec Pharmalab IPO achieved a 3.24 times subscription rate by 12:30 PM on Wednesday, August 26, its second day. Bids totaling 4,24,78,215 shares matched the total shares offered.

Key Subscription Numbers

• Non-institutional investor (NII) category: 6.32 times subscribed
• Retail individual investor (RII) segment: 3.44 times subscribed
• Qualified Institutional Buyers (QIB) portion: 0.55 times subscribed

This initial public offering aims to raise ₹1,757 crore. The issue includes a fresh issue of shares valued at up to ₹150 crore and an Offer For Sale (OFS) of ₹1,607 crore.

IPO Structure and Purpose

• Fresh issue proceeds: Used for debt clearance and general corporate purposes
• Offer For Sale by: Satwani Holdings LLP, Rosewood Investments, India Business Excellence Fund-III
• Minimum application: 15 shares

Before the main offering, Symbiotec Pharmalab secured ₹526 crore from anchor investors. Major participants included HDFC Mutual Fund, Motilal Oswal Mutual Fund, and ICICI Prudential Mutual Fund, among others.

Crucial IPO Dates

• Subscription period: August 24 to August 27
• Allotment finalization: August 28
• Refund initiation and Demat credit: August 31
• Listing on NSE and BSE: September 1

Indore-based Symbiotec Pharmalab operates as a research and development-driven pharmaceutical and biotechnology firm. The company specializes in complex injectables, organic chemistry, and biotechnology, recognized as a global leader in steroidal-hormone and corticosteroid active pharmaceutical ingredients (APIs).

Avendus Capital, Motilal Oswal, JM Financial, and Nomura Financial are serving as the book-running lead managers for the IPO. MUFG Intime India is the registrar.

Strategic Benefits of Listing

The company expects its stock exchange listing to enhance visibility, bolster brand image, and establish a public market for its equity shares in India.